MX2024001939A - Administracion retrograda de composicion terapeutica mediante seno o vena coronarios. - Google Patents

Administracion retrograda de composicion terapeutica mediante seno o vena coronarios.

Info

Publication number
MX2024001939A
MX2024001939A MX2024001939A MX2024001939A MX2024001939A MX 2024001939 A MX2024001939 A MX 2024001939A MX 2024001939 A MX2024001939 A MX 2024001939A MX 2024001939 A MX2024001939 A MX 2024001939A MX 2024001939 A MX2024001939 A MX 2024001939A
Authority
MX
Mexico
Prior art keywords
therapeutics
coronary venous
retrograde coronary
therapeutic
sinus administration
Prior art date
Application number
MX2024001939A
Other languages
English (en)
Spanish (es)
Inventor
Arthur M Feldman
Valerie Myers
Marcia Bologna
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Publication of MX2024001939A publication Critical patent/MX2024001939A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024001939A 2021-08-12 2022-08-12 Administracion retrograda de composicion terapeutica mediante seno o vena coronarios. MX2024001939A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163260225P 2021-08-12 2021-08-12
US202163263442P 2021-11-02 2021-11-02
US202263343985P 2022-05-19 2022-05-19
PCT/US2022/074944 WO2023019272A1 (en) 2021-08-12 2022-08-12 Retrograde coronary venous or sinus administration of therapeutics

Publications (1)

Publication Number Publication Date
MX2024001939A true MX2024001939A (es) 2024-07-10

Family

ID=85201030

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001939A MX2024001939A (es) 2021-08-12 2022-08-12 Administracion retrograda de composicion terapeutica mediante seno o vena coronarios.

Country Status (10)

Country Link
US (1) US20260069719A1 (https=)
EP (1) EP4384269A4 (https=)
JP (1) JP2024529170A (https=)
KR (1) KR20240063110A (https=)
AU (1) AU2022325237A1 (https=)
CA (1) CA3228581A1 (https=)
CL (1) CL2024000397A1 (https=)
IL (1) IL310763A (https=)
MX (1) MX2024001939A (https=)
WO (1) WO2023019272A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117010A2 (en) 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 as a target for therapy of heart failure
WO2024229259A1 (en) * 2023-05-02 2024-11-07 Research Institute At Nationwide Children's Hospital Gene therapy for treatment of protein misfolding diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117010A2 (en) * 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 as a target for therapy of heart failure
SG11201803934YA (en) * 2015-11-11 2018-06-28 Intrexon Corp Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies

Also Published As

Publication number Publication date
AU2022325237A1 (en) 2024-03-21
IL310763A (en) 2024-04-01
AU2022325237A2 (en) 2024-03-28
EP4384269A4 (en) 2026-03-18
KR20240063110A (ko) 2024-05-10
CL2024000397A1 (es) 2024-08-30
JP2024529170A (ja) 2024-08-01
EP4384269A1 (en) 2024-06-19
US20260069719A1 (en) 2026-03-12
CA3228581A1 (en) 2023-02-16
WO2023019272A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
CL2024000397A1 (es) Administración de agentes terapéuticos por vía venosa coronaria retrógrada o sinusal
MX2022000143A (es) Metodos novedosos.
CL2021001810A1 (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
ECSP22049008A (es) M?todos de tratamiento del c?ncer de pulm?n de c?lulas peque?as con formulaciones de lurbinectedina
RU2747124C2 (ru) Способы лечения метастатического рака поджелудочной железы с помощью комбинированной терапии, включающей применение иринотекана и оксалиплатина
AR120399A1 (es) Un método de tratamiento de un cáncer positivo para dll3
BR112013004698A2 (pt) composições farmacêuticas compreendendo derivados de poh
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
MX2021011230A (es) Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
PE20190351A1 (es) Agente terapeutico del sindrome de hunter y metodo de tratamiento
MX2020003756A (es) Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2015014939A (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
CO2020001322A2 (es) Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante
EA202090558A1 (ru) Схемы лечения
MX374938B (es) Un método para el tratamiento de trastornos del movimiento con befiradol.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2022005448A (es) Método de tratamiento de queratodermia palmoplantar.
CL2021000444A1 (es) Métodos para reducir el riesgo de diabetes en pacientes tratados por enfermedades relacionadas con el colesterol alto.
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas
WO2014145199A8 (en) Retrograde delivery of sdf-1 for treatment of myocardial infarction
GEAP202416526A (en) Treatment of major depressive disorder
MX2023011355A (es) Combinacion terapeutica para tratar el cancer.
Nakano Cisplatin/dexamethasone/warfarin interaction